Ahead of ASCO, Merck Touts Another Win for Lung Cancer Drug Combo

The rapidly changing treatment landscape for lung cancer could soon change again. This morning, Merck (NYSE: MRK) announced that a Phase 3 study called Keynote-407 has succeeded. The trial tested a co…
Read the full story: Xconomy